Lyvgen Announces Ph 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in NSCLC Patients November 30, 2022
FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers November 30, 2022
Positive Update On Joint TIGIT Program From Interim Analysis Of ARC-7 Study In NSCLC Announced November 30, 2022
ARV-471 Achieves a CBR of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Ph 2 Expansion Trial (VERITAC) November 30, 2022
Ph 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma November 30, 2022
U.S. FDA Accepts for Priority Review the BLA for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of R/R Large B-Cell Lymphoma November 30, 2022
FDA issued CRL indicating the poziotinib application cannot be approved in its present form; company to deprioritise the program November 30, 2022
FDA Clears IND Application for BCMA CAR-T CB-011 for the Treatment of R/R Multiple Myeloma November 30, 2022
ENHERTU® Approved in Japan for Patients with Previously Treated HER2 Positive Metastatic Breast Cancer November 30, 2022
